Myth or not? Uncover the facts about what makes this therapy a first choice for patients with RMS, from its long-term efficacy data, including NEDA-3, to its proven safety and tolerability profile.
This event is provided by Novartis Pharmaceuticals Corporation. This material was developed and approved exclusively for a US audience.
